» Articles » PMID: 23296510

The Twin Epidemics of Tuberculosis and HIV

Overview
Date 2013 Jan 9
PMID 23296510
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The deadly combination of tuberculosis (TB) and human immunodeficiency virus (HIV) currently ravaging the world, taking a toll of about 0.35 million people every year, is one of the major public health crises of the decade. Throughout the course of HIV infection, the risk of acquisition, reactivation, and reinfection of TB keeps increasing substantially as the immune deficiency progresses. TB coinfected patients inadvertently facilitate HIV infection by release of the proinflammatory cytokines and overexpression of coreceptors CXCR4 and CCR5; thereby, the progression of each is facilitated. The difficulties in diagnosing active tuberculosis in HIV-infected individuals poses a great challenge that is further complicated by the challenges in identification of latent TB infection, creating a setback to preventive therapy. Furthermore, prescribing antituberculous therapy and antiretroviral therapy together poses several management challenges, including drug interactions, added toxicities, and TB immune reconstitution inflammatory syndrome. The current approach to diagnosis, prevention, and treatment strategies in TB and HIV coinfected individuals, along with epidemiology and overview of pathogenetic interplay of both microbes, is reviewed here.

Citing Articles

Predictors of tuberculosis infection among adults visiting anti-retroviral treatment center at east and west Gojjam, northwest, Ethiopia, 2017.

Belew H, Wubie M, Tizazu G, Bitew A, Birlew T BMC Infect Dis. 2020; 20(1):593.

PMID: 32787798 PMC: 7422613. DOI: 10.1186/s12879-020-05290-2.


Drug-Induced Ototoxicity: Diagnosis and Monitoring.

Campbell K, Le Prell C Drug Saf. 2018; 41(5):451-464.

PMID: 29404977 DOI: 10.1007/s40264-017-0629-8.


Tuberculosis, human immunodeficiency virus, and the immune reconstitution inflammatory syndrome.

Rapose A, Karande S J Postgrad Med. 2017; 63(4):207-209.

PMID: 29022559 PMC: 5664861. DOI: 10.4103/jpgm.JPGM_365_17.


Tuberculosis Elimination Efforts in the United States in the Era of Insurance Expansion and the Affordable Care Act.

Balaban V, Marks S, Etkind S, Katz D, Higashi J, Flood J Public Health Rep. 2015; 130(4):349-54.

PMID: 26345625 PMC: 4547565. DOI: 10.1177/003335491513000413.


Assessment of nutrient supplement to reduce gentamicin-induced ototoxicity.

Le Prell C, Ojano-Dirain C, Rudnick E, Nelson M, DeRemer S, Prieskorn D J Assoc Res Otolaryngol. 2014; 15(3):375-93.

PMID: 24590390 PMC: 4010593. DOI: 10.1007/s10162-014-0448-x.

References
1.
Lawn S, Myer L, Edwards D, Bekker L, Wood R . Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS. 2009; 23(13):1717-25. PMC: 3801095. DOI: 10.1097/QAD.0b013e32832d3b6d. View

2.
Narayanan S, Swaminathan S, Supply P, Shanmugam S, Narendran G, Hari L . Impact of HIV infection on the recurrence of tuberculosis in South India. J Infect Dis. 2010; 201(5):691-703. DOI: 10.1086/650528. View

3.
Menzies D, Al Jahdali H, Al Otaibi B . Recent developments in treatment of latent tuberculosis infection. Indian J Med Res. 2011; 133:257-66. PMC: 3103149. View

4.
Abdool Karim S, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A . Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010; 362(8):697-706. PMC: 3076221. DOI: 10.1056/NEJMoa0905848. View

5.
Perucca E, Grimaldi R, Frigo G, Sardi A, Monig H, Ohnhaus E . Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects. Eur J Clin Pharmacol. 1988; 34(6):595-9. DOI: 10.1007/BF00615223. View